Bicara Therapeutics (NASDAQ:BCAX) Given “Overweight” Rating at Cantor Fitzgerald

Bicara Therapeutics (NASDAQ:BCAX)‘s stock had its “overweight” rating reissued by equities researchers at Cantor Fitzgerald in a note issued to investors on Thursday,Benzinga reports. They currently have a $13.01 price objective on the stock. Cantor Fitzgerald’s target price indicates a potential upside of 4.75% from the company’s current price.

A number of other analysts have also recently weighed in on BCAX. HC Wainwright upped their price target on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, January 27th. Wedbush reaffirmed an “outperform” rating and set a $31.00 price target on shares of Bicara Therapeutics in a research report on Wednesday, February 12th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Bicara Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $36.50.

Bicara Therapeutics Price Performance

Shares of Bicara Therapeutics stock opened at $12.42 on Thursday. The business’s fifty day simple moving average is $13.19. Bicara Therapeutics has a twelve month low of $11.10 and a twelve month high of $28.09.

Hedge Funds Weigh In On Bicara Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vestal Point Capital LP boosted its position in Bicara Therapeutics by 67.1% in the 4th quarter. Vestal Point Capital LP now owns 710,000 shares of the company’s stock valued at $12,368,000 after buying an additional 285,000 shares during the last quarter. Wexford Capital LP purchased a new position in Bicara Therapeutics in the 4th quarter valued at about $348,000. Red Tree Management LLC purchased a new position in Bicara Therapeutics in the 4th quarter valued at about $55,230,000. Nuveen Asset Management LLC purchased a new position in Bicara Therapeutics in the 4th quarter valued at about $436,000. Finally, Orbimed Advisors LLC boosted its position in Bicara Therapeutics by 9.7% in the 4th quarter. Orbimed Advisors LLC now owns 298,301 shares of the company’s stock valued at $5,196,000 after buying an additional 26,391 shares during the last quarter.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.